通过抑制降解恢复RUNX1家族性血小板病中的RUNX1缺陷
RUNX1家族性血小板病(RUNX1-FPD)由RUNX1单等位基因突变引起,RUNX1活性约为正常一半,表现为血小板减少、功能缺陷及白血病易感。RUNX1经泛素-蛋白酶体途径快速降解并可能自调节表达。研究假设药理学抑制RUNX1降解可恢复蛋白水平、血小板数量与功能并延缓恶性转化。研究评估了细胞系、患者来源诱导多能干细胞、原代骨髓细胞及RUNX1突变急性髓系白血病细胞,发现短暂表达外源RUNX1或抑制泛素化/蛋白酶体降解步骤可在体外恢复RUNX1水平并促进巨核细胞分化。
要点
- RUNX1-FPD由RUNX1单等位基因突变导致RUNX1活性约减半。
- 抑制RUNX1泛素化或蛋白酶体降解可在体外恢复RUNX1水平。
- 恢复RUNX1水平可促进巨核细胞分化,提示延缓RUNX1降解或为治疗方向。
核心结论
- 药理学抑制RUNX1蛋白降解可能恢复RUNX1水平、改善血小板减少与功能缺陷,并可能延缓或预防RUNX1-FPD恶性转化。
研究设计与样本
- 研究评估了细胞系、RUNX1-FPD患者来源诱导多能干细胞、RUNX1-FPD原代骨髓细胞及RUNX1突变急性髓系白血病患者血液细胞。
主要发现
- 短暂表达外源RUNX1或抑制导致RUNX1泛素化和蛋白酶体降解的步骤,在某些情况下可恢复RUNX1水平。
- 恢复RUNX1水平可在体外促进巨核细胞分化。
临床怎么用
- 延缓RUNX1蛋白酶体降解的药物可能成为治疗RUNX1-FPD出血并发症和预防白血病的治疗途径。
局限性
- 研究主要为体外实验,临床疗效与安全性尚未在患者中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RUNX1 familial platelet disorder (RUNX1-FPD) is an autosomal dominant disorder caused by a monoallelic mutation of RUNX1, initially resulting in approximately half-normal RUNX1 activity. Clinical features include thrombocytopenia, platelet functional defects, and a predisposition to leukemia. RUNX1 is rapidly degraded through the ubiquitin-proteasome pathway. Moreover, it may autoregulate its expression. A predicted kinetic property of autoregulatory circuits is that transient perturbations of steady-state levels result in continued maintenance of expression at adjusted levels, even after inhibitors of degradation or inducers of transcription are withdrawn, suggesting that transient inhibition of RUNX1 degradation may have prolonged effects. We hypothesized that pharmacological inhibition of RUNX1 protein degradation could normalize RUNX1 protein levels, restore the number of platelets and their function, and potentially delay or prevent malignant transformation. In this study, we evaluated cell lines, induced pluripotent stem cells derived from patients with RUNX1-FPD, RUNX1-FPD primary bone marrow cells, and acute myeloid leukemia blood cells from patients with RUNX1 mutations. The results showed that, in some circumstances, transient expression of exogenous RUNX1 or inhibition of steps leading to RUNX1 ubiquitylation and proteasomal degradation restored RUNX1 levels, thereby advancing megakaryocytic differentiation in vitro. Thus, drugs retarding RUNX1 proteolytic degradation may represent a therapeutic avenue for treating bleeding complications and preventing leukemia in RUNX1-FPD.
引用
- Krutein MC, Hart MR, Anderson DJ, et al. Restoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation. Blood Adv. 2021. PMID: 33560381. doi:10.1182/bloodadvances.2020002709
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。